TNF inhibitors and radiographic progression in axSpA
Dec 03, 2021
News
A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.
Telemedicine Upside Interview with Dr. Alvin Wells
Dec 03, 2021
Rheumatoid Arthritis, Dementia and Cognitive Dysfunction
Dec 02, 2021
Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies..
Methotrexate and hepatic fibrosis: we must be doing something right
Dec 02, 2021
Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity.
New Insights into Uveitis in Spondyloarthritis
Dec 01, 2021
Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.
Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles
Dec 01, 2021
Prolonging the Controversy of Hydroxychloroquine
Nov 30, 2021
Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.
DORIS - Defining Remission in Lupus
Nov 29, 2021
Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE. A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016.
Giant Cell Arteritis Novel Treatment Options
Nov 29, 2021
RheumNow Podcast - 60/40/20 Interview with Dr. Ed Keystone
Nov 26, 2021
Dr. Jack Cush interviews Professor Edward Keystone, MD (University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.
Risankizumab for Active Psoriatic Arthritis
Nov 26, 2021
The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis.
Better assessment and management of multimorbidity
Nov 26, 2021